Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Mixed Share Performance [Yahoo! Finance]
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: Yahoo! Finance
Tarsus Pharmaceuticals overview after recent share performance Tarsus Pharmaceuticals (TARS) has seen mixed share performance recently, with a decline over the past 3 months but a gain over the past month. This has prompted fresh attention on its valuation and business profile. See our latest analysis for Tarsus Pharmaceuticals. At a share price of $73.26, Tarsus Pharmaceuticals reflects mixed recent momentum, with a 13.37% 1 month share price return contrasting with a weaker year to date share price performance. The 1 year and 3 year total shareholder returns remain very strong, which may hint at changing risk and growth expectations being priced in. If this kind of move has you looking beyond a single name, it could be a good moment to broaden your search with our screener of 32 healthcare AI stocks as potential next ideas to research. With Tarsus showing strong multi year returns but softer recent performance, the key question now is whether the current price and valuati
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Tarsus Pharmaceuticals (TARS) was upgraded by Lifesci Capital to "strong-buy".MarketBeat
- Tarsus Pharmaceuticals, Inc. (TARS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating [Yahoo! Finance]Yahoo! Finance
- Tarsus Pharmaceuticals (TARS) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TARS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from MarketBeat
- Tarsus Pharmaceuticals (TARS) was downgraded by Zacks Research from "strong-buy" to "hold".MarketBeat
TARS
Earnings
- 2/23/26 - Miss
TARS
Sec Filings
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- TARS's page on the SEC website